Canagliflozin (hemihydrate): SGLT2 Inhibition in Diabetes Research

Executive Summary: Canagliflozin (hemihydrate) is a small molecule SGLT2 inhibitor used extensively for glucose metabolism and diabetes mellitus research, exhibiting high purity (≥98%) as verified by HPLC and NMR (product information). Its chemical profile—C₂₄H₂₆FO_5.5S, MW 453.52—supports robust solubility in ethanol (≥40.2 mg/mL) and DMSO (≥83.4 mg/mL), but not water. It targets renal glucose reabsorption via SGLT2 inhibition, making it a core tool for dissecting glucose homeostasis pathways in preclinical settings. Peer-reviewed evidence confirms Canagliflozin does not inhibit mTOR/TOR signaling in model systems, clarifying its pathway specificity (GeroScience 2025). The APExBIO C6434 kit is intended for research use only and should be stored at -20°C for optimal stability.

Biological Rationale

Diabetes mellitus and related metabolic disorders are characterized by impaired glucose homeostasis. The sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubule reabsorbs filtered glucose, contributing to systemic glucose levels. Pharmacological inhibition of SGLT2 reduces renal glucose reabsorption, lowering blood glucose concentrations without directly stimulating insulin secretion (see related review; this article further details selectivity benchmarks and mechanistic specificity). Canagliflozin (hemihydrate) provides a selective means to modulate renal glucose handling in experimental models. This precision is essential for dissecting renal versus pancreatic contributions to glucose metabolism and for benchmarking translational interventions in diabetes research.

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate), synonymous with JNJ 28431754 hemihydrate, acts by reversibly inhibiting SGLT2 in the renal proximal tubule. This reduces the reabsorption threshold of glucose, increasing urinary glucose excretion. The compound does not inhibit SGLT1 at clinically relevant concentrations, preserving intestinal glucose absorption and minimizing gastrointestinal side effects (see prior article; this article updates with recent mTOR selectivity data). Molecularly, Canagliflozin binds to SGLT2's active site, blocking sodium-dependent glucose transport. Its action is concentration-dependent, and it remains inactive against unrelated signaling pathways such as the mTOR/TOR axis (reference study).

Evidence & Benchmarks

• Canagliflozin (hemihydrate) demonstrates ≥98% purity by HPLC/NMR, supporting reproducible experimental outcomes (product information).
• Solubility exceeds 40.2 mg/mL in ethanol and 83.4 mg/mL in DMSO, but is negligible in water, guiding solvent selection for in vitro and in vivo protocols (product information).
• Canagliflozin does not inhibit the mTOR/TOR signaling pathway in drug-sensitized yeast models, confirming pathway selectivity and avoiding off-target effects (GeroScience 2025).
• Renal glucose reabsorption inhibition by Canagliflozin leads to increased urinary glucose excretion without direct effects on pancreatic insulin secretion (internal review; this article clarifies mTOR independence).
• APExBIO supplies Canagliflozin (hemihydrate) as SKU C6434 with COA and MSDS documentation for research use only (product page).

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is widely employed in glucose metabolism research, diabetes mellitus modeling, and studies of renal glucose handling. Its SGLT2 selectivity makes it suitable for dissecting the glucose homeostasis pathway in both translational and mechanistic investigations (internal synthesis; this article expands protocol parameters and mTOR selectivity evidence). However, it is not an mTOR inhibitor and shows no activity against TOR signaling pathways in validated yeast-based assays (GeroScience 2025).

Common Pitfalls or Misconceptions

• Canagliflozin (hemihydrate) is not suitable for mTOR/TOR pathway inhibition studies, as confirmed by drug-sensitized yeast assays.
• Long-term storage of prepared solutions is not recommended due to potential compound degradation; fresh solutions should be used promptly (product information).
• Water is not an effective solvent for Canagliflozin (hemihydrate) due to negligible solubility; ethanol or DMSO are required for both stock and working solutions.
• Intended strictly for research use; not for diagnostic, therapeutic, or clinical application.
• SGLT2 inhibition does not directly alter insulin secretion or pancreatic beta cell activity.

Workflow Integration & Parameters

• Solubility preparation: Dissolve in DMSO (preferred for in vitro) at ≥83.4 mg/mL or ethanol at ≥40.2 mg/mL for maximal stock concentration (product page).
• Storage conditions: Store powder at -20°C, protected from light and moisture. Ship with blue ice for small molecule stability.
• Solution handling: Prepare fresh aliquots before each experiment; avoid repeated freeze-thaw cycles.
• Assay context: Use in glucose uptake, renal reabsorption, or metabolic flux assays; not for mTOR pathway inhibition studies (GeroScience 2025).
• Concentration guidelines: Typical in vitro concentrations range from 10 nM to 10 μM, depending on assay sensitivity.

Conclusion & Outlook

Canagliflozin (hemihydrate) provides a high-specificity, high-purity SGLT2 inhibition tool for advanced diabetes and glucose metabolism research. Its lack of mTOR pathway activity, confirmed in a sensitive yeast-based screening system, supports its selectivity and appropriateness for pathway-specific studies (GeroScience 2025). Researchers should note critical solvent and storage parameters for reliable results. For expanded protocol detail and translational benchmarking, the APExBIO product page and related in-depth articles offer further guidance.